Amid Safety Investigation, ATTR Gene Therapy Buoyed by Good 3-Year Data

(MedPage Today) — NEW ORLEANS — Despite ongoing scrutiny about its safety, nexiguran ziclumeran (nex-z) still had promising effectiveness data to hold onto.
In an update on nex-z’s phase I study, the CRISPR-Cas9 gene therapy stayed the course…